CN106432090B - 一种氘代咪唑酮化合物的晶型及其制备方法和用途 - Google Patents
一种氘代咪唑酮化合物的晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN106432090B CN106432090B CN201610609034.XA CN201610609034A CN106432090B CN 106432090 B CN106432090 B CN 106432090B CN 201610609034 A CN201610609034 A CN 201610609034A CN 106432090 B CN106432090 B CN 106432090B
- Authority
- CN
- China
- Prior art keywords
- crystal form
- solvent
- dimethyl
- fluoro
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015107263252 | 2015-10-30 | ||
CN201510726325 | 2015-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106432090A CN106432090A (zh) | 2017-02-22 |
CN106432090B true CN106432090B (zh) | 2019-08-20 |
Family
ID=58184308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610609034.XA Active CN106432090B (zh) | 2015-10-30 | 2016-07-28 | 一种氘代咪唑酮化合物的晶型及其制备方法和用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN106432090B (zh) |
TW (1) | TWI638810B (zh) |
WO (1) | WO2017071375A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478347B (zh) * | 2018-05-14 | 2021-07-02 | 海创药业股份有限公司 | 一种hc-1119制剂及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
CN104341352A (zh) * | 2013-08-09 | 2015-02-11 | 南京衡杰生物科技有限公司 | 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2908326C (en) * | 2013-05-29 | 2017-09-12 | Hinova Pharmaceuticals Inc. | Imidazolidinedione compounds and their uses |
-
2016
- 2016-07-28 CN CN201610609034.XA patent/CN106432090B/zh active Active
- 2016-08-17 WO PCT/CN2016/095647 patent/WO2017071375A1/zh active Application Filing
- 2016-09-07 TW TW105128872A patent/TWI638810B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
CN104341352A (zh) * | 2013-08-09 | 2015-02-11 | 南京衡杰生物科技有限公司 | 作为雄激素受体拮抗剂的二芳基乙内酰脲化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
TW201714878A (zh) | 2017-05-01 |
CN106432090A (zh) | 2017-02-22 |
WO2017071375A1 (zh) | 2017-05-04 |
TWI638810B (zh) | 2018-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9701641B2 (en) | Enzalutamide polymorphic forms and its preparation | |
US20180051026A1 (en) | Polymorphs of ibrutinib | |
WO2012066565A2 (en) | Asenapine maleate amorphous and crystalline form and process for preparation thereof | |
AU2020276695A1 (en) | New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer | |
US20200247753A1 (en) | Polymorphs and co-crystals of roxadustat | |
CN108774200A (zh) | 化合物的结晶复合物,其制备方法及其用于制备药物的用途 | |
US11084791B2 (en) | Solid state forms of Lenvatinib Mesylate | |
WO2016023905A1 (en) | New and efficient process for the preparation of crystalline form 6 of sofosbuvir | |
Lee et al. | Solution enhanced dispersion by supercritical fluids (SEDS): An approach in particle engineering to modify aqueous solubility of andrographolide from Andrographis paniculata extract | |
CN105693734B (zh) | 一种特质ε-HNIW晶体及其制备方法 | |
PT107166B (pt) | Síntese e engenharia de partículas de cocristais | |
CN106432090B (zh) | 一种氘代咪唑酮化合物的晶型及其制备方法和用途 | |
WO2021000687A1 (zh) | Pac-1晶型的制备方法 | |
CN109438467B (zh) | 一种硫酸氢氯吡格雷ⅱ型球形结晶的制备方法 | |
CN104045547B (zh) | 一种丙酮酸钠重结晶制取方法 | |
EP4003970A1 (en) | Methods of preparing synthetic cannabinol and homologs thereof | |
WO2016108204A1 (en) | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | |
AU2015224847C1 (en) | Iohexol powder and method of using the same | |
WO2013008250A2 (en) | Crystalline form of retigabine and processes for mixture of retigabine crystalline modifications | |
CN104151324A (zh) | 一种溶媒结晶法制备氨苄西林钠的方法 | |
CN106432266B (zh) | 一种阿洛西林钠晶体及其制备方法 | |
JP2008285446A (ja) | (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法 | |
JPS5817728B2 (ja) | アンピシリンナトリウムエン ノ セイホウ | |
JP2003517036A (ja) | 物質から微量溶媒を除去するための方法 | |
WO2023187086A1 (en) | Amorphous solid form of amcenestrant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170222 Assignee: Sichuan Haisco Pharmaceutical Co.,Ltd. Assignor: Chengdu SeaBird pharmaceutcal corporation, Ltd Contract record no.: 2017510000037 Denomination of invention: Crystal form of deuteration imidazolone compound and preparation method and use of crystal form License type: Exclusive License Record date: 20171114 |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No.2 and No.3, floor 4, building 1, Rongyao building, No.5 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Patentee after: Haichuang Pharmaceutical Co., Ltd Address before: 801, C1 incubation building, Tianfu Life Science Park, 88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Patentee before: Chengdu Haichuang Pharmaceutical Co.,Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd. Assignor: Chengdu Haichuang Pharmaceutical Co.,Ltd. Contract record no.: 2017510000037 Date of cancellation: 20210312 |